Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520337 | 0.79 | TSHR (0.48) | KDM4EMAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL866607 | 0.78 | RAB9A (0.58) | KDM4EMAPTTSHRNPC1PKM | |
| SCHEMBL6343183 | 0.77 | MAPT (0.40) | KDM4EMAPTTSHRNPC1PKM | |
| SCHEMBL3827167 | 0.77 | — | — | |
| SCHEMBL27972868 | 0.76 | MAPT (0.45) | KDM4EMAPTTSHRNPC1PKM | |
| SCHEMBL26999712 | 0.76 | KDM4E (0.42) | KDM4EMAPTTSHRNPC1PKM | |
| SCHEMBL1396292 | 0.76 | MAPT (0.45) | KDM4EMAPTTSHRNPC1PKM | |
| Hydrochloric Acid SCHEMBL3821986 | 0.75 | BAZ2B (0.35) | TSHRNPC1PKMNFKB1RAB9A | |
| SCHEMBL17813161 | 0.74 | KMT2A (0.46) | KDM4EMAPTTSHRNPC1PKM | |
| SCHEMBL19500072 | 0.74 | KDM4E (0.41) | KDM4EMAPTTSHRNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655302-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4615848-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF | Ribometrix, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615441-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF | Ribometrix, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024159097-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024103067-A1 | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | RIBOMETRIX, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024103067-A1 | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | RIBOMETRIX, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-117567498-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-112262139-B | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| WO-2010044543-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | 주식회사 네오팜 (KR) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-0648764-B1 | N-(substituted amino)pyrrole derivatives, preparation process thereof, and herbicidal compositions | KUREHA CHEMICAL IND CO LTD (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5612287-A | N-(substituted amino) pyrrole derivatives preparation process thereof, and herbicidal compositions | KUREHA KAGAKU KOGYO K.K. (JP) | 1997-03-18 | — | — | US | disclosed |
| US-5604178-A | N-(substituted amino)pyrrole derivatives, and herbicidal compositions | KUREHA KAGAKU KOGYO K.K. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0648764-A1 | N-(substituted amino)pyrrole derivatives, preparation process thereof, and herbicidal compositions | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | KDM4E 471/4885MAPT 4198/4885TSHR 3312/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | KDM4E 1830/4885MAPT 2052/4885TSHR 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.